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ABSTRACT
Objective: To investigate the influence of the increased use of intrapartum chemoprophylaxis on the
incidence of vertically transmitted neonatal sepsis.
Methods: Multiple institutional databases were queried for the number of cases in which intra-
partum antibiotics were used, the obstetric risk factors that were present, and the number of
resultant cases of neonatal sepsis that occurred for deliveries from 1992 through 1997. Intrapartum
antibiotic use was compared between the first and fourth quarter of 1997. Comparisons were made
between the years 1992-1996 and 1997 for the incidence of the various pathogens causing neonatal
sepsis; group B streptococcus (GBS), gram-negative sepsis, and others.
Results: We found a significant increase in intrapartum chemoprophylaxis between the first and
fourth quarters of 1997 corresponding to the increased physician awareness ofpublished guidelines.
As expected, the incidence of neonatal GBS sepsis was drastically reduced (from 1.7/1000 live
births to 0 in 3730 births, P 0.02). Unfortunately, there was a concomitant increase in the
incidence of gram-negative sepsis (0.29/1000 vs. 1.3/1000, P .02). The overall incidence of neo-
natal sepsis remained unchanged (2.7/1000 vs. 2.1/1000, P .69).
Conclusions: Published guidelines have encouraged physicians to increase the use of intrapartum
chemoprophylaxis to reduce vertical transmission of GBS. This study confirms the efficacy of this
approach. Unfortunately, this reduction comes at the cost of increasing the incidence of ampicillin-
resistant gram-negative neonatal sepsis with a resultant increased mortality. These data provide
compelling evidence that the policy of providing ampicillin chemoprophylaxis in selected patients
needs to be reconsidered. Infect. Dis. Obstet. Gynecol. 7:210-213, 1999. (C) 1999Wiley-Liss, Inc.
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hile gram-negative neonatal sepsis (GNNS)
has long been recognized as a clinical entity,
it has been largely overshadowed in the last decade
by discussions regarding group B streptococcal
(GBS) neonatal sepsis. This is primarily a result of
the historically higher incidence of GBS than
GNNS. In July 1996, a communication was issued
from the Centers for Disease Control and Preven-
tion (CDC) that recommended providing intrapar-
turn chemoprophylaxis for the prevention of neo-
natal GBS. While there were other recommenda-
tions that preceded this, namely those of the
American Academy of Pediatricsz and the Ameri-
can College of Obstetricians and Gynecologists,
3
the CDC’s recommendation may have lessened
some of the confusion in this area for some profes-
sionals.
In our center, clinical practice began to change
following the CDC communication, with an in-
creased use of intrapartum antibiotics. Two years
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Fig. I. Incidence of neonatal sepsis and intrapartum antibiotic use. GNS, gram-negative neonatal sepsis.
later we reviewed the impact of this change in
clinical practice on the incidence of newborn GBS
and GNNS by examining the perinatal statistics in
our institution for the past 6 years. Specifically, we
examined the prevalence of intrapartum antibiotic
use and the incidence of GBS and GNNS prior to
and subsequent to the CDC recommendation.
SUBJECTS AND METHODS
Early neonatal sepsis was defined as a positive
blood and/or cerebrospinal fluid culture within the
first 7 days of life. The Infection Control Surveil-
lance database was queried for all such cases of
neonatal sepsis with identification of the causative
organism. Neonatal morbidity and mortality statis-
tics and maternal data were obtained by querying
our proprietary computerized perinatal database of
20,981 consecutive live births from January 1, 1992,
through December 31, 1997.
The incidence of obstetric risk factors known to
be associated with neonatal sepsis was also specifi-
cally reviewed for this time period. The risk factors
that were recognized as relevant to this review
included preterm delivery, prolonged rupture of
membranes (>18 hr), prior urine culture positive for
GBS, and intrapartum fever. Cases of chorioamni-
onitis were not excluded from the analysis.
Antibiotic usage was ascertained by querying
the hospital’s pharmacy information system for an-
tibiotics administered in the labor and delivery
suites. Individual chart reviews were performed for
those cases with pharmacy ampicillin orders in
which no risk factor was identified in the computer
record to determine the actual risk factor(s) for
these patients. The computer record was then ap-
propriately updated as a result of the chart review.
The remainder of the patients who received anti-
biotics in labor and delivery and who had risk fac-
tors prospectively identified were confirmed as
having received intrapartum antibiotics.
A comparison was then made between the inci-
dence of GBS and GNNS for the years 1992
through 1996 and that occurring in 1997, the first
full year following the publication of the CDC
guidelines. The relative use of intrapartum antibi-
otics during those two time periods, 1992-1996 and
1997, was compared as well.
Chi square analysis was used for comparisons of
these discrete variables using the shareware com-
puter program, Epistat.
RESULTS
The total number of deliveries, incidence of risk
factors and neonatal sepsis, and percentage of pa-
tients receiving intrapartum antibiotics were re-
viewed for each quarter of 1997. The percentage of
patients with one or more risk factors remained
stable throughout 1997, with 27% in the 1st quarter
and 27% in the 4th quarter. The percentage of
patients who received antibiotics while in labor for
their deliveries, however, increased significantly
from the 1st quarter (3%), reflecting the level of
use prior to 1997, to the 4th quarter (16%), P
0.00001. This is depicted in Figure 1.
There were 21,569 deliveries from 1992 through
1997, yielding 17,251 live births for the years 1992
through 1996 and 3,730 live births during 1997.
Data were divided into two groups: pre-1997 and
1997 deliveries. There were 30 cases of GBS dur-
ing the pre-1997 period, for an incidence of 1.7/
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Fig. 2. Incidence of neonatal sepsis by pathogen. GNS, gram-negative neonatal sepsis.
TABLE I. Cases of GNNS during 1997
Delivery Gestational Prophylaxis
D date age Risks given? Organism Outcome
I/i 1/97 27 wk Yes Yes
2 6/I 7/97 34 wk Yes No
3 8/5/97 24 wk Yes Yes
4 9/20/97 28 wk Yes Yes
5 10/21/97 38 wk No No
Otrobacter (ampicillin resistant)
Klebsiella (ampicillin resistant)
Klebsiella & Enterobacter (ampicillin resistant)
E. coli (ampicillin resistant)
E. coli (ampicillin resistant)
Died
Died
Discharged
Died
Discharged
1000 live births.4 Five cases of GNNS occurred
during that same period, for an incidence of 0.29/
1000 live births. During 1997, coincident with the
increased use of intrapartum antibiotics, there were
no cases of GBS and five cases ofGNNS (1.3/1000
live births). This represents a significant decrease
of GBS rates (from 1.7 to 0/1000 live births, P
0.02) with a concomitant 4.5-fold increase in
GNNS cases (from 0.29 to 1.3/1000 live births,
odds ratio 4.63 with 95% confidence limits of 1.22
and 17.57, P 0.02). The total number of cases of
neonatal sepsis, including organisms other than
GBS and GNNS (eg, enterococcus, staphylococ-
cus), did not vary from pre-1997 to 1997 (2.7/1000
live births for 1992-1996, and 2.1/1000 live births in
1997, P 0.69; see Fig. 2).
The individual cases of GNNS during 1997 are
listed in Table 1. There were three deaths among
the five cases ofGNNS in 1997, for a mortality rate
of 60%. Four of the five cases (80%) had risk factors
for which three of the mothers received antibiotic
prophylaxis with ampicillin, it could not be deter-
mined whether or not the other two mothers had
received antibiotics antepartum. All pathogens re-
covered from the positive blood cultures in the
neonates were resistant to ampicillin.
DISCUSSION
intrapartum antibiotic use in our institution in-
creased dramatically following the publication of
the CDC guidelines. It is not clear why there was
so little chemoprophylaxis provided prior to this,
given the recommendations of other organizations
preceding the CDC’s recommendations. Our de-
partment provides care to both public and private
patients, from both resident and private attending
physicians, and there has been no consistently ap-
plied protocol for GBS prophylaxis applied to pa-
tients presenting to labor and delivery by the pro-
viders in our institution. Nonetheless, the vast ma-
jority of providers now give GBS chemoprophylaxis
based on risk factors seen on presentation in labor.
in addition, the antimicrobial choice has always
been ampicillin, except for patients with intrapar-
tum fever, in which case, cefoxitin is typically pro-
vided (despite the fact that the CDC suggests that
penicillin G is the preferred choice of a chemopro-
phylactic agent).
With the increased rate of intrapartum chemo-
prophylaxis in our institution, we observed a sig-
nificant decrease in the incidence of GBS neonatal
sepsis, as expected. Unfortunately, this was accom-
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panied by a corresponding rise in the incidence of
GNNS. It should also be noted that the overall
incidence of neonatal sepsis remained unchanged
following this increased intrapartum chemoprophy-
laxis.
In our institution, Escherichia coli isolates are re-
sistant to the main beta-lactam antibiotic used, am-
picillin, at least 50% of the time, with the other
Enterobacteriaceae species often having an even
greater resistance to ampicillin. One can then pos-
tulate that ampicillin may select for the growth of
potentially pathogenic gram-negative bacilli, gen-
erally known to colonize the female lower genital
tract and act as the reservoir for organisms that may
subsequently cause the vertically transmitted neo-
natal sepsis. This may indicate a causal linkage be-
tween increased perinatal ampicillin use and in-
creased incidence of GNNS. Our findings appear
similar to those reported by McDuffie et al.s and
further justify the recommendations offered by
Amstey and Gibbs6 that penicillin be used instead
of ampicillin for GBS chemoprophylaxis. It should
be emphasized that we found the mortality rate
from GNNS (60%) to be 10-fold higher than that of
GBS (6.7%), a circumstance not unlike that found
elsewhere. 7,8
In conclusion, the increased use of intrapartum
ampicillin has, as predicted, decreased the rate of
neonatal GBS sepsis in our institution. However,
this has been accomplished at the cost of increasing
GNNS, with attendant increased morbidity and
mortality. This finding should cause concern for
those health care providers responsible for prevent-
ing and treating infections of the perinate, and we
believe these associations merit further investiga-
tion. If these findings are confirmed elsewhere, it
may be time to reexamine our policies on intrapar-
tum chemoprophylaxis, as they may be doing our
neonates more harm than good.
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